Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up

Rheumatology (United Kingdom)

Volumn 55, Issue 1, 2016, Pages 143-148

  Chen, Der Yuan ^a,b,c   Chen, Yi Ming ^a,b   Hsieh, Tsu Yi ^a   Hung, Wei Ting ^a   Hsieh, Chia Wei ^a,b   Chen, Hsin Hua ^a,b   Tang, Kuo Tung ^a,b   Lan, Joung Liang ^d,e  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Adalimumab; Dose reductio; Drug troungh level; Rheumatoid arthritis; Therapeutic responses

Indexed keywords

ADALIMUMAB; DRUG ANTIBODY; HYDROXYCHLOROQUINE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; DAS28; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

EID: 84960125348     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev298     Document Type: Article

References (20)

1. Kievit W, Fransen J, Adang EMM et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch rheumatoid arthritis monitoring register. Rheumatology 2011;50:196-203.
2. Krieckaert CL, Nair SC, Nurmohamed MT et al. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Ann Rheum Dis 2015;74:361-8.
3. Chatzidionysiou K, Turesson C, Teleman A. A multicenter, randomized, controlled open-label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients in stable clinical remission. Arthritis Rheum 2012;64(Suppl):S336.
4. Smolen JS, Nash P, Durez P et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918-29.
5. den Broeder AA, van der Maas A, van den Bemt B. Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA. Rheumatology 2010;49:1801-3.
6. Pouw MF, Krieckaert CL, Nurmohamed MT et al. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis 2015;74:513-8.
7. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
8. Ledingham J, Deighton C; British Society for Rheumatology Standards, Guidelines and Audit Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005;44:157-63.
9. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology 2004;43:1252-5.
10. Chen DY, Chen YM, Tsai WC et al. Significant associations of antidrug antibodies levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis 2015;74:e16.
11. Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
12. Tanaka Y, Hirata S, Kubo S et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis 2015;74:389-95.
13. den Broeder AA, Creemers MC, van Gestel AM, van Riel PL. Dose titration using the disease activity score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-α. Rheumatology 2002;41:638-42.
14. Bartelds GM, Krieckaert CL, Nurmohamed MT et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8.
15. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
16. Hart MH, de Vrieze H, Wouters D et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods 2011;372:196-203.
17. van Schouwenburg PA, Bartelds GM, Hart MH et al. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals ''hidden'' immunogenicity in rheumatoid arthritis. J Immunol Methods 2010;362:82-8.
18. vas PA, Krieckaert CL, Rispens T et al. Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis 2013; 72:1680-6.
19. Bloem K, van Leeuwen A, Verbeek G et al. Systemic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J Immunol Methods 2015;418:29-38.
20. Burmester GR, Kivitz AJ, Kupper H et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 2015;74:1037-44.